Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Puma

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

Sarepta investigating mistakenly submitted Duchenne therapy report

Study participant fell seriously ill

- PMLiVE

AbbVie files blockbuster hopeful elagolix for uterine fibroids

Will face competition from Myovant rival

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

- PMLiVE

Pfizer set to unveil Mylan merger and spin-off

Follows consumer health deal with GSK

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

- PMLiVE

Myovant has second phase 3 trial to back its uterine fibroids drug

Aims to take on AbbVie in new market

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

AbbVie cures STING fever with Mavupharma acquisition

Joins host of companies pursuing novel mechanism

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

Battling breast cancer with precision medicine (Part 1)

Laura Holmes Haddad is a breast cancer survivor. She made the incredibly brave decision to participate in a PARP inhibitor precision medicine trial. Here, the author and precision medicine advocate...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links